<DOC>
	<DOCNO>NCT01277744</DOCNO>
	<brief_summary>The goal clinical research study learn heat intra-abdominal cisplatin help control abdominal tumor patient surgery remove tumor . The safety drug also study .</brief_summary>
	<brief_title>Pilot Study Hyperthermic Peritoneal Perfusion ( HIPEC ) Adolescent Young Adults With Desmoplastic Small Round Cell Tumor</brief_title>
	<detailed_description>The Study Drugs : Cisplatin platinum atom center . The platinum suppose poison cancer cell , may cause die . Surgery Study Drug Administration : If find eligible , abdominal surgery perform try remove many tumor possible . The abdominal surgery perform specifically research study would perform even n't take part study . You give separate consent form sign explain detail risk abdominal surgery detail . During surgery receive sodium thiosulfate vein . The abdomen temporarily close . Then abdominal wash begin . During `` abdominal wash , '' heat cisplatin deliver plastic tubing connect pump abdomen . The pump push heat cisplatin abdomen pull recirculates cisplatin . The skin abdomen temporarily close abdominal wash . The surgeon also `` wash '' close area surgical site . A pump use pump heat cisplatin abdomen 90 minute surgeon gently press abdominal wall cisplatin reach area abdomen . After 90 minute , cisplatin remove abdomen `` wash '' saline fluid remove surgeon permanently close abdomen 3 layer stitch . Two ( 2 ) pea-sized tumor sample send laboratory Dr. Dina Lev tissue evaluation extraction RNA ( genetic material ) . One ( 1 ) tumor sample remove procedure sample remove end procedure . The sample examine microscope DNA ( genetic material cell ) remove look change DNA . The result test share , use decision regard treatment . The sample destroy test complete . There chance surgeon may decide surgery abdominal wash perform , example disease spread attach certain organ . If occurs , doctor discus treatment option . Study Visits : On Days 1-5 , 11 , 14 , ( Day 1 day surgery ) : - Blood ( 1 teaspoon ) drawn routine test . - You physical exam , include measurement weight vital sign . Follow-Up Visits : About 1 , 3 , 6 month surgery complete , follow-up visit follow test procedure perform : - You physical exam , include measurement weight vital sign . - Blood ( 1 teaspoon ) draw 1 month visit routine test . - You hear test 1 month visit . - Blood ( 3 teaspoon ) draw routine test 3 6 month visit . - At 3 6 month visit , CT scan , PET-CT scan , MRI scan check status disease . Length Study : You remain study 6 month . You take study disease get bad . If study doctor learn disease come back gotten bad 6 month follow-up visit , may eligible re-perfusion , repeat operation study drug administration . If eligible re-perfusion , participation study end give new consent form sign order re-enrolled back onto study . This investigational study . Cisplatin FDA-approved commercially available treatment advance bladder cancer , metastatic testicular cancer , metastatic ovarian cancer , hepatoblastoma , neuroblastoma , metastatic appendiceal cancer , abdominal mesothelioma . The use cisplatin patient abdominal sarcoma-type tumor investigational . Up 22 patient take part study . All enrol MD Anderson .</detailed_description>
	<mesh_term>Fever</mesh_term>
	<mesh_term>Desmoplastic Small Round Cell Tumor</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<criteria>1 . Age great equal 1 year 2 . Histologically genetically proven diffuse peritoneal retroperitoneal tumor desmoplastic round cell tumor , ovarian germ cell , sarcoma , Wilms ' tumor , noncarcinoma tumor . 3 . Radiologic workup must demonstrate disease confine abdominal cavity 4 . Radiologic workup prior abdominal exploration must consistent disease debulked residual size less equal 1 cm thickness per tumor deposit 5 . Patients must minimum expected duration survival great 6 week determine documented attend surgeon medical oncologist . 6 . Patients must systemic illness precludes operative candidate determine anesthesia preoperative evaluation . This include limited , sepsis , liver failure , pregnant lactating female . 7 . Patients must fully intact mental status normal neurologic ability . Intact mental status define 'the capacity identify recall one 's identity place time space . ' Assessment mental status documentation fully intact mental status complete use physical mental exam refer doctor oncologist . 8 . Patients must adequate renal function ( serum creatinine &lt; /= 1.5 mg/dl without history dialysis renal failure creatinine clearance le 50 mL/min/1.73M^2 less 5 year age ) 9 . Patients eligible WBC &gt; /=2000/microliter ANC &gt; /=1,500 platelet &gt; /= 100,000/mm^3 10 . Patients eligible serum total bilirubin liver enzymes &lt; /=2 time upper limit normal 11 . Patients must recover toxicity prior chemotherapy , immunotherapy , radiotherapy least 14 day past date last treatment 1 . Patients ineligible concomitant cardiopulmonary disease would place unacceptable risk major surgical procedure 2 . Patients ineligible disease outside abdominal cavity uncontrolled 3 . Patients ineligible baseline neurologic toxicity Grade 3 great ( potential neurotoxicity associate platinum ) 4 . Patients fail previous intraperitoneal platinum therapy ineligible 5 . Patients Retroperitoneal Liposarcoma ineligible .</criteria>
	<gender>All</gender>
	<minimum_age>1 Year</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Desmoplastic small round cell tumor</keyword>
	<keyword>DSRCT</keyword>
	<keyword>Hyperthermic peritoneal perfusion</keyword>
	<keyword>HIPEC</keyword>
	<keyword>Complete abdominal tumor excision</keyword>
	<keyword>Extensive abdominal disease</keyword>
	<keyword>Non-carcinoma tumor</keyword>
	<keyword>Abdominal cavity</keyword>
	<keyword>Cisplatin</keyword>
	<keyword>Platinol-AQ</keyword>
	<keyword>Platinol</keyword>
	<keyword>CDDP</keyword>
	<keyword>Diffuse peritoneal tumor</keyword>
	<keyword>Retroperitoneal tumor</keyword>
	<keyword>Ovarian germ cell</keyword>
	<keyword>Wilms ' tumor</keyword>
</DOC>